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 Restriction digests are a commonly utilized process for cleaving DNA at specific, 
but relatively common sites. Restriction enzymes have widespread use in DNA 
manipulation. CRISPR/Cas9 is a recently identified endonuclease which utilizes a 
customizable guide sequence to recognize and cut specific ~20 bp sites located in a DNA 
sequence. This preliminary research aimed to exploit the potential benefit of DNA 
restriction using the CRISPR/Cas9 procedure through alterations of different components 
involved in that system. We sought to refine existing CRISPR/Cas9 protocols and make a 
budget friendly, user-selectable CRISPR/Cas9 restriction digest protocol. The motivation 
for this research was to simplify and adapt known CRISPR protocols in hopes of using 
CRISPR as a targeted restriction enzyme. This project yielded negative results, however, 
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1.1 A Brief History of Genetic Improvement after Mendel’s Research 
 Over 150 years ago Gregor Mendel identified segregation patterns in pea plants 
(Mendel 1866), leading to a revolution in our understanding of inheritance (van Dijk et 
al., 2018). Mendel’s work was focused on determining the mathematical concepts of how 
plants pass on traits to progeny (Mendel 1866). Despite his incredible achievement, 
Gregor Mendel’s work would not be rediscovered until the early 1900’s (Moore, 2001). 
The contribution of Mendel’s work would see immediate success in helping plant 
breeders efficiently use cross-breeding to introduce desired traits in plant varieties 
(Larkin, 1986). The plant variants generated from crossbreeding have increased yields in 
various crop types across the world over the span of the last 100 years. In North America 
alone, corn yield has increased from approximately 2 tonnes per hectare in 1940 to over 
10 tonnes per hectare in 2014 (Ritchie and Roser, 2019) and worldwide cereal production 
has nearly tripled over the course of 1961 to 2014. Though past (and present) biological 
research has drawn extensively from the findings of Mendel (Figure 1.1), there are 
limitations to the cross-breeding of plants. While cross-breeding is faster than trait 
selection in plants, the long time and high expense it may take to get “pure lines” with 
desired traits is still a major concern (Larkin, 1986). The biggest drawback to using cross-




number of traits that can be introduced in new lines of plants is limited by the amount of 




Figure 1.1. Timeline of restriction enzymes’ discovery with general historical landmarks.  
 
 Through the years 1889 to 1907 Thomas Boveri carried out a series of 
experiments investigating sea urchins and their chromosomes (Boveri, 1889, 1902, 1905, 
1907). The result of Boveri’s research was a better understanding of how important 
chromosomes are in embryonic development (Laubichler and Davidson, 2008). In 1902 
Walter Sutton published a paper about his work with grasshoppers and their 
chromosomes where he submitted his revelations regarding chromosomes (Sutton 1902). 
In 1903 Sutton published another paper which divulged more about the significance of 
chromosomes and helped further establish a connection between Mendel’s thoughts on 
heredity and chromosomes (Sutton 1903). As a result of their contributions the Boveri-
Sutton chromosome theory took shape (O'Connor and Miko, 2008). In 1910, Thomas 




1910). In a short amount of time his experiments yielded the evidence needed to establish 
the link between chromosomes and heredity (Morgan, 1910). With Morgan’s contribution 
confirming what Boveri and Sutton had postulated years prior, the theory of chromosome 
inheritance was developed (Gleason, 2017). 
 In 1928 Frederick Griffith carried out a series of experiments with bacteria of the 
pneumococcal species; these experiments showed that bacteria could acquire new genetic 
information through a “transformation factor” (Griffith, 1928). Griffith’s experiment 
served as a basis for an experiment conducted by Oswald Avery, Colin Macleaod, and 
MacLynn McCarty in 1943; this experiment pointed to DNA as the genetic material 
(Avery et al., 1943). In 1953 James Watson and Francis Crick discovered the structure of 
DNA by analyzing pre-existing x-ray diffraction results and building models of DNA 
(Watson and Crick 1953).  
 In the late 1950’s and into the early 1960’s Francis Crick proposed a theory as to 
how the relationship between DNA to RNA and RNA to proteins could function. This 
relationship was referred to as the central dogma of biology (Crick, 1958). His theory was 
shown to be true and this relationship amongst genetic material is a key factor in 







Figure 1.2. A diagram of the Central Dogma. Provided by Dr. Shultz. 
 
 The onset of genetic engineering began with research into recombinant DNA in 
the late 1960’s (Jackson et al., 1972). The first experiment utilizing recombinant DNA 
was reported by David Jackson in 1971. This experiment involved the early use of 
restriction enzymes. 
 By the 1980’s, genetic engineering had opened a new facet of research (Berg and 
Mertz, 2010) and led to the development of several tools utilized to edit gene sequences 
as shown in Figure 1.3. These tools include restriction enzymes, zinc finger nucleases 
(ZFNs), transcription activator-like endonucleases (TALENs), and clustered regularly 







Figure 1.3. The different types of restriction enzymes; ZFN and TALEN sequences 
specificity relates to specific triplet or limited specific bp sequences respectively. Pink 
highlights represent binding sites for indicated restricition enzyme or endonuclease. Bold 





1.2 Restriction Enzymes 
 Restriction enzymes are defensive mechanisms that help protect bacterial DNA 
from being altered by viral DNA. This is accomplished by compromising the viral DNA 
through cleavage (Loenen et al., 2014). Restriction enzymes were initially discovered in 
the 1950’s (Roberts, 2005) but were not truly understood until the 1960’s (Loenen et al., 
2014).  Studies investigated interactions between the phage Lambda and bacterial DNA, 
revealing that bacteria exposed to bacteriophages could use restriction enzymes to defend 
against a viral attack. Initial studies observed that bacteriophages had varying degrees of 
success when attacking different strains of the same type of bacteria (Roberts, 2005). The 
varying success of the bacteriophage was predicted to be the result of enzymatic reactions 
that modify DNA (Roberts, 2005). The next significant study saw the purification of 
restriction enzymes from E. coli and the subsequent testing of how these enzymes select 
cleaving sites (Loenen et al., 2014).  
 There are currently 4 types of restriction enzymes (Table 1.1, Figure 1.3). Type 1 
restriction enzymes were the first to be discovered and were determined to be a defense 
mechanism against DNA entry utilized by E. coli and other enteric bacteria (Loenen et 
al., 2014). Type 2 restriction enzymes are the broadest category and feature enzymes that 
recognize specific patterns in DNA and cleave at or near these sites (Pingoud et al, 2014). 
Type 3 enzymes have an intermediate function between type 1 and type 2 restriction 
enzymes (Loenen et al., 2014). Type 4 is the rarest type and only works with modified 






Table 1.1. Types of Restriction Enzymes  (Loenen et al., 2014) 
 
1.3 Zinc Finger Nucleases and Transcription Activator-Like Endonucleases 
 Zinc Finger Nucleases (ZFNs) were the first chimeric endonucleases to be created 
and had some success when used for gene editing (Amitai and Sorek, 2016). ZFNs have a 
modular design  featuring domains which recognize nucleotide triplets. These nucleases 
have a critical disadvantage that would be overcome by future nucleases, namely the 
specificity that must be adhered to when designing these nucleases. They are specific, but 
so specific that their design does not lend well to being flexible for research. 
Transcription Activator-Like Endonucleases (TALENs) incorporate similar technology to 
ZFNs (Amitai and Sorek, 2016). TALENs offer a unique improvement when compared to 
ZFNs  because their domains match with individual nucleotides. Their inherent flexibility 
offers a wider array of applications and an easier system to utilize; their flexibility led to 
ZFNs as a research tool.  
 
1.4 CRISPR Associated Protein/ CRISPR-Cas9 
 Clustered Regularly Interspaced Short Palindromic Repeats/ CRISPR associated 
protein (CRISPR-Cas) is a DNA editing tool that was discovered as a result of research 
into the ‘adaptive’ immunity of bacteria (Richter et al., 2012). This DNA-editing 
technology utilizes a unique guide-RNA which targets a selected DNA site through 
complementary base-pair alignment (Loureiro and Da Silva, 2019). Once the CRISPR-
Enzymes Features 
      Type 1 Cleave variably, often far from the recognition site 
Type 2 Cleave within or at fixed positions close to recognition site 
Type 3 Cleave at fixed position outside of recognition site 




Cas9/gRNA complex binds to the target site, a double strand break (DSB) is created in 
the DNA sequence (Loureiro and Da Silva, 2019). This break can be further utilized by 
either allowing DNA repair mechanisms to create a new sequence in this spot or by 
inserting a custom sequence (Loureiro and Da Silva, 2019). 
 The guide sequence that Cas9 utilizes is composed of CRISPR RNA (crRNA) and 
trans-activating CRISPR RNA (tracrRNA) (Amitai and Sorek, 2016).  Both crRNA and 
tracrRNA are necessary for CRISPR-Cas9 to successfully target a DNA sequence (Figure 
1.4). These two components must work in conjunction with a protospacer adjacent motif 
(PAM) site located downstream from the target DNA sequence. (Amitai and Sorek, 
2016). The combination of crRNA and tracrRNA can be used in a pre-created guide 
sequence known as single guide RNA (sgRNA).  CRISPR/Cas9 has not made TALEN 
technology obsolete, however it has offered a viable alternative to TALENs that can be 
utilized in unique ways at a lower cost with simpler materials. 
 
  
Figure 1.4. Functional components of the CRISPR-Cas9 system (Bortesi, L. and Fischer, 
R., 2014). Panel (a) shows the individual RNA components necessary for proper Cas9 





1.5 Project Goals 
  The motivation for this research was to simplify and adapt known CRISPR 
protocols in hopes of using CRISPR as a targeted restriction enzyme. The developed 
protocol would be utilized as a molecular biology tool. CRISPR can take the basic 
application of restriction enzymes and improve upon that function by supplying a vast 
array of specific target sites that restriction enzymes do not have the flexibility to 
recognize. Our objective was to combine the function of a restriction enzyme with the 
specificity of ZFN/TALEN procedures by using CRISPR/Cas9 to knock out a specific 
gene. This was done in the hopes of making Cas9 more accessible and simpler to use. 
The simplest way of carrying out CRISPR/Cas9 reactions is by manipulating/changing 
sgRNA sequences. The major drawback of using sgRNA sequences is the cost associated 
with these sequences. The smallest sample size offered by IDT on their website is a 2 
nmol sample of sgRNA at 195.00$ a sequence (IDT, 2019). 
 A total of three different hypotheses were tested within this study. 
H1, A unique, user-selectable restriction digest protocol can be created for 
CRISPR-Cas9 by adapting and altering current CRISPR-Cas9 protocols.  
 H2, The designed protocol will be effective at incorporating unconventional guide  
 sequences to be used in conjunction with Cas9. 
H3, The designed CRISPR-Cas9 protocol will have increased cleavage specificity 









MATERIALS AND METHODS 
 
 
2.1 Source of DNA and Primer Design 
 Promega Lambda DNA (Cat. # D1501) was used in this project. Stock DNA was 
diluted to a 1:40 working ratio for all PCR reactions. This particular source of Lambda 
DNA has proven reliable through multiple iterations of Genetics and PCR Methods 
laboratory courses (Shultz, 2019). 
 A primer pair (Forward 5’- TAAATTCGCACAGCAGCAAC -3’; Reverse 5’- 
ACGTTTTCAGGTTGGCATTC -3’) was created to amplify a 1,000bp region of the 
Lambda phage genome (GenBank ID: J02459.1). Lyophilized IDT primer tubes were 
spun down in a microcentrifuge, then TE buffer (Promega, cat. # PAV6231) was added to 
each primer (10 x nmol value). The primer tubes were then briefly centrifuged and placed 
in a 60
o
C heat block for 60 minutes, then spun down. Next, 400uL of molecular biology 
grade water was pipetted into a labeled dilution tube, followed by 50uL of the left and 
50uL of the right primers.  
 PCR reactions were prepared to test primer functionality. A master mix of 100uL 
GoTaq, 30uL molecular biology water, and 30uL Lambda (1:40) DNA template was 
created. Eighteen microliters of the master mix was aliquoted into 12 PCR tubes. Two 
microliters of primers were added to each PCR tube. The PCR tubes were spun down and 





at 95° C, 35 cycles of denaturing for 60 seconds at 95° C, annealing for 75 seconds at 60° 
C, and extending for 45 seconds at 72° C, and a final extending period for 5 minutes at 
72° C. All samples were held at 10
o
 C until removed from the thermal cycler. 
 After the PCR program was run, the products were loaded in an agarose gel. The 
gel was run for an hour at 160V to confirm that they produced a 1000bp band. A picture 
of the gel was taken using UVP documentation system (BioDoc-It Imaging System, M-
26).  The primers were then used to create identical PCR reactions for use as stock PCR 
product for subsequent experiments. 
 
2.2 CRISPOR Program 
The CRISPOR program (Haeussler, M., and Concordet, J., 2019) was used to 
identify potential target sequences for Cas9 within the 1,000 bp PCR product and five 
guide sequences were selected. These five sequences were ordered as “crDNA,” which is 
to say that they mimic traditional crRNA sequences, but have the structure of DNA 
(Table 2.1). These “crDNAs” were also ordered with uracil replacing the thymine (Table 
2.1). 
 




(bp)  Sequence 
  SeqT1  151/fw           5’-AGAGCAGAAAAAGACCTGGG-3’ 
SeqT2 210/fw           5’-TGAAGTCCGGCTGGAGTGAG-3’ 
SeqT3 404/fw           5’-GTGGGGATTGTCGGGAGTAT-3’ 
SeqT4 635/fw           5’-ATGCGCGGCTATGCCACCGG-3’ 
SeqT5 766/fw           5’-AGGTCCGGCTGCTCTGAAGG-3’ 
DNA Sequences with Uracil 
SeqU1 151/fw           5’-AGAGCAGAAAAAGACCUGGG-3’ 
SeqU2 210/fw           5’-UGAAGUCCGGCUGGAGUGAG-3’ 
SeqU3 404/fw           5’-GUGGGGAUUGUCGGGAGUAU-3’ 
SeqU4 635/fw           5’-AUGCGCGGCUAUGCCACCGG-3’ 





2.3 Origene Functionality Test  
Experiment 1 was conducted by adhering closely to the steps and reagents 
recommended in the Origene protocol (Origene, 2019). Duplex reactions were made to 
combine the crDNA and tracrDNA sequences by mixing 1uL of 100uM crRNA, 1uL of 
100uM tracrRNA (IDT, cat. # 1072533), and 8uL of nuclease-free duplex buffer (IDT, 
cat. # 11010301); this was done individually for all guide sequences used. The guide 
sequences used for this protocol included the following: 210, 635, 210U, and 635U 
(Table 2.1). The duplex reactions were heated at 95 degrees Celsius for 5 minutes and 
then cooled to room temperature.  
 Four solution types were made by diluting one of each of the following in 
nuclease free water: stock crDNA, stock crDNA containing Uracil, crDNA with 
tracrRNA, and crDNA containing Uracil with tracrRNA. Three different concentrations 
of the stock DNA were made using nuclease free water. The Cas9 reagent  (NEB, cat. # 
M0386T) was diluted immediately before the experiment took place by using a mixture 
containing reaction buffer (NEB, cat. # B0386) diluted in nuclease free water. Each guide 
sequence sample was diluted from an initial concentration of 100uM to a final 
concentration of 1uM in nuclease free water.  
The two tubes that contained both guide sequences and tracrRNA were then 
diluted from 10uM to 1uM by putting 1uL of the initial solution into 9uL of nuclease free 
water. Three DNA template tubes were prepared by diluting the original concentration of 
1.264uM to the following concentrations: 100uL total solution 1uL DNA, 1.5uL DNA 
and 6uL DNA. There were diluted with 99uL, 98.5uL, and 94uL nuclease-free water, 





1x by using 2uL of 10x buffer and 17uL of nuclease-free water. One Cas9 working 
solution tube was prepared. The Cas9 (NEB, cat. # M0386T) was diluted from 20uM to 
1uM in 1X buffer and 1uL of nuclease-free water.  Overall, 1uL of Cas9 (NEB, cat. # 
M0386T), 2uL of 1x buffer, and 17uL nuclease-free water were combined and then used 
immediately. 
In total 14 reactions tubes were made. The first 12 reactions contained either 
crDNA or crDNA-U and no tracrRNA was added. Four different crDNAs were used 
which were comprised of 2 crDNA and 2 crDNA-U sequences. Three different 
concentrations of DNA template were used 
2
/3, 1, and 4 times the calculated value. The 
other 2 reactions were standard, but had crDNA and crDNA-U with tracrRNA added.  
The reactions were prepared by mixing the following:  21uL of nuclease-free 
water, 2.9uL of 10X Cas9 nuclease reaction buffer, 1uL of 1uM sgRNA , 1uL of 1uM 
Cas9 Nuclease (NEB, cat. # M0386T), and 1uL of template DNA with one of the the 
three concentrations prepared. The contents were mixed and spun down in a 
microcentrifuge. The reactions were incubated at 37 
o
C for 1 hour, then heated at 65 
o
C 
for 10 minutes to deactivate the Cas9 nuclease (NEB,  cat. # M0386T). Sample sizes of 
12uL were taken from each reaction tube and electrophoresed in order to determine band 
size. 
 
2.4 Adapted Origene Protocol 
 The second experiment featured the crDNA and crDNA with uracil segments 
used in conjunction with wtCas9 (Table 2.1, Table 2.2). The second experiment also 
followed the Origene protocol but featured increased concentrations of template DNA 





100uM crDNA and 1uL of 100uM tracrRNA (IDT, cat. # 1072533)  with 8uL of nuclease 
free duplex buffer (IDT, cat. # 11010301). Each tube was prepared with a unique crDNA; 
either 635 or 635U crDNA sequences. The duplex tubes were heated at 95 
o
C for 5 
minutes and were cooled to room temperature. 
 Four guide DNA tubes were prepared next and served as dilution tubes for the 
sequences that were being tested (635, 635U, 210, and 210U). The guides were diluted 
from an initial molarity of 100uM to 1uM by pipetting 1uL of stock guide DNA into 
99uL of nuclease-free water. 
 Two duplex working solution tubes were prepared by diluting 1uL of 10uM stock 
duplex solution into 9uL of nuclease-free water for a final dilution of 1uM. A Cas9 
dilution tube was made by combining 2uL of 10x Cas9 reaction buffer (NEB, cat. # 
B0386) and 17uL of nuclease-free water. One microliter of 20uM Cas9 (NEB,  cat. # 
M0386T) was added to the solution immediately before the reaction tubes were 
assembled. 
 Twelve reaction tubes were made. Six reactions contained 15uL of nuclease free 
water, 2.9uL of 10X Cas9 nuclease reaction buffer, 1uL of 1uM guide DNA, 1uL of 1uM 
Cas9 (NEB, cat. # M0386T), and 10uL of undiluted PCR product. These 6 reactions 
contained the following guides: 635, 635U, 210, 210U, 635 with tracrRNA, and 635U 
with tracrRNA. The second set (3X Cas9 set) was comprised of 6 reactions that contained 
the following: 13uL of nuclease-free water, 2.9uL of 10X Cas9 nuclease reaction buffer, 
1uL of 1uM sgRNA, 3uL of 1uM Cas9 nuclease (NEB,  cat. # M0386T), 10uL of 
undiluted PCR product. The contents were mixed and spun down in a microcentrifuge. 
The reactions were incubated at 37 
o
C for 1 hour, then heated at 65 
o





deactivate the Cas9 nuclease (NEB,  cat. # M0386T). A total of 12uL were taken from 
each reaction tube and electrophoresed in order to determine band size. 
 
2.5 IDT Protocol Functionality Test 
Experiment 3 incorporated the Alt-R Cas9 protocol from IDT (IDT, 2019). Four 
duplex tubes were made by mixing crDNA, tracrRNA (IDT, cat.# 1072533) and 
nuclease-free duplex buffer (IDT, cat. # 11010301). The final concentration was 10uM, 
which was done by mixing 1uL of 100uM crDNA with 1uL of 100uM tracrRNA in 8uL 
of nuclease-free duplex buffer. The duplex tubes were heated at 95
o
 Celsius for 5 
minutes. The duplex tubes were then cooled to room temperature. A dilution of the DNA 
template was then prepared using 2uL of DNA template diluted into 48uL of nuclease-
free water. 
The RNP complex tubes were prepared for both the NEB and IDT Cas9 tubes.  A 
total of 8 tubes were made; 4 with NEB Cas9 (cat. # M0386T) and 4 with IDT Alt-R 
Cas9 (cat. # 1081058). These mixtures were prepared by mixing the crDNAs with Cas9 
in PBS. The NEB Cas9 RNPs were prepared by mixing 2uL of 10uM guide DNA with 
1uL of 20uM NEB Cas9 (cat. # M0386T) in 17uL of PBS. The Alt-R Cas9 tubes were 
made by combining 5uL of 10uM guide DNA with .8uL of 62uM Alt-R Cas9 in 44.2 uL 
of PBS. Both sets of tubes were incubated at room temperature for approximately 10 
minutes. 
A total of twelve reactions were prepared. Four of these reactions were NEB Cas9  
(cat. # M0386T) and another 4 were Alt-R Cas9. The last 4 reactions varied the amount 
of DNA in the reaction tubes. These reactions included the following reagents: 10X 





The four reactions made with NEB Cas9 (NEB,  cat. # M0386T) were made with the 
following amounts: 1uL of 10X Cas9 reaction buffer, 1uL of 1uM NEB Cas9 RNP 1uL, 
1uL of 50nM DNA substrate, and 7uL of nuclease-free water. The four reactions made 
with Alt-R Cas9 were made with the following amounts: 1uL of 10X Cas9 reaction 
buffer, 1uL of 1uM Alt-R Cas9 RNP 1uL, 1uL of 50nM DNA substrate, and 7uL of 
nuclease-free water. The 4 extra reactions were made with 3 times the amount of 
template DNA. These reactions were then incubated at 37
o 
C for 60 minutes. Each 
reaction had 1uL of proteinase K added before a final incubation step of 10 minutes at 
56
o
C. A total of 12uL were taken from each reaction tube and electrophoresed in order to 
determine band size. 
 
2.6 Adapted IDT and Origene Protocol 
The final series of reaction sets featured new guide sequences based off of the 
crDNA sequences used in the prior reactions (Table 2.2). These new sequences were 
dubbed sgDNA sequences because they included both the original crDNA sequence as 
well as a series of base pairs that were designed to mimic a standard tracrRNA sequence. 
Because these sequences contained the mimicked tracrRNA sequence, no tracrRNA was 

























The first reaction sets were prepared using the IDT protocol. Tubes were prepared 
by putting 1uL of sgDNA 210 and sgDNA 635 into tubes labelled d210 and d635 
respectively. The  D210 and D635 tubes were diluted by putting 9uL of nuclease-free 
water into both tubes. Tubes were labelled as gCas210 and gCas635 and had 1uL of Alt-
R Cas9 (IDT, cat. # 1081058) , 44uL of PBS, and 5uL of d210 and d635 respectively. All 
gCas tubes were incubated at room temperature for approximately 10 minutes.  Tubes 
were prepared as follows: 210-1 with 1uL of gCas210, 210-2 with 2uL of gCas210, 210-4 
with 4uL of gCas210, 210-8 with 8uL of gCas210, 635-1 with 1uL of gCas623, 635-2 
with 2uL of gCas635, 635-4 with 4uL of gCas635, and 635-8 with 8uL of gCas635. Next, 
2uL of nuclease-free reaction buffer (NEB, cat. # B0386) was added to each reaction 
tube. After this, 6uL of template DNA was added to each tube. Nuclease-free water was 
added to each tube in the following amounts: 11uL to 210-1 and 635-1, 10uL to 210-2 
and 635-2, 8uL to 210-4 and 635-4, and 4uL to 210-8 and 635-8. These reactions were 
then incubated at 37
o 
C for 60 minutes. Each reaction had 1uL of proteinase K added 
before a final incubation step of 10 minutes at 56
o
C. 
Individual reactions were prepared by putting 1uL of sgDNA 210 and sgDNA 635 





by adding 9uL of nuclease-free water. Tubes were labelled as gCas210 and gCas635 and 
had 1uL of NEB Cas9 (cat. # M0386T), 44uL of PBS, and 5uL of d210 and d635 
respectively. All gCas tubes were incubated at room temperature for approximately 10 
minutes. Reactions were prepared as follows: 210-1 with 1uL of gCas210, 210-2 with 
2uL of gCas210, 210-4 with 4uL of gCas210, 210-8 with 8uL of gCas210, 635-1 with 
1uL of gCas623, 635-2 with 2uL of gCas635, 635-4 with 4uL of gCas635, and 635-8 
with 8uL of gCas635. Next, 2uL of nuclease-free reaction buffer (NEB, cat. # B0386) 
was added to each reaction, followed by 6uL of template DNA. Nuclease-free water was 
added to each tube in the following amounts: 11uL to 210-1 and 635-1, 10uL to 210-2 
and 635-2, 8uL to 210-4 and 635-4, and 4uL to 210-8 and 635-8.. These reactions were 
then incubated at 37
o 
C for 60 minutes. Each reaction had 1uL of proteinase K added 
before a final incubation step of 10 minutes at 56
o
C. 
The last reaction set was prepared using the Origene protocol. Dilution tubes were 
labelled as d210 and d635; they had 1uL of sgDNA added to each tube. Next, 99uL of 
water was added to each tube. A Cas9 dilution was prepared by putting 4uL of nuclease-
free reaction buffer (NEB, cat. # B0386), 34uL of water, and 2uL of Cas9 (NEB,  cat. # 
M0386T). 1uL of sgDNA into tubes labelled: 210-1, 210-2, 210-4, 210-8, 210-12, 635-1, 
635-2, 635-4, 635-8, and 635-12. A total of 8uL template DNA was added to each 
reaction tube, followed by 2.9uL reaction buffer.  Water was added to each reaction tube 
in the following amounts: 1uL to 210-1 and 635-1, 2uL to 210-2 and 635-2, 4ul to 210-4 
and 635-4, 8uL to 210-8 and 635-8, and 12uL to 210-12 and 635-12. The contents were 
mixed and spun down in a microcentrifuge. The reactions were incubated at 37 
o
C for 1 
hour, then heated at 65 
o





M0386T). Finally, a total of 12uL were taken from each reaction tube and 


















3.1 Primer Design 
The primer pair designed to amplify a 1,000bp region in the lambda genome 
amplified the desired product size. The PCR product was tested and verified via gel 
electrophoresis as shown in Figure 3.1. Both wells containing PCR product showed bands 




Figure 3.1. Gel electrophoresis of Lambda DNA with designed primers (target size 
1000bp). Well 1 shows a size standard (indicated with “M”) and wells 2 and 3 show 
successful PCR. 
 
3.2 Origene Protocol Functionality Test 
 The first experiment using NEB Cas9 nuclease in conjunction with the Origene 





produce a visible Cas9 restriction product. The reactions that had four times the DNA 
amount were visible on the gel but were very faint and still localized to the 1000bp 
region. The concentrated PCR product used as a size standard was very bright in every 
well it was present. Wells 2-4, 6-8, 10-12, and 14-16 show failed CRISPR-Cas9 reactions 
which utilized crDNA sequences only. Wells 18 and 19 show failed CRISPR-Cas9 




Figure 3.2. Gel electrophoresis of the Origene-based CRISPR-Cas9 protocol. Wells 
containing ladders are labeled with “L”. Wells containing uncut, stock PCR product are 
labeled “P”. The labels 
2
/3,1X and 4X indicate the concentration of DNA used in the 
reaction. The standard concentration was 1X. Wells 2-4, 6-8, 10-12, 14-16, 18, and 19 
show CRISPR/Cas9 reaction products. 
 
3.3 Adapted Origene Protocol 
 The apparent dimness of the resulting DNA was further explored in the second 
experiment with an increased amount of DNA template (Figure 3.3). The amount of Cas9 
was increased for some of these reactions in order to further test that variable. The 
resulting bands were as bright as the size standard controls in wells 2 and 16. Wells 3-8 





CRISPR-Cas9 reactions which utilized crDNA sequences only, but with pure, non-
diluted template DNA; all other reagent concentrations remained unaltered form the 
original protocol. Wells 7 and 8 show failed CRISPR-Cas9 reactions which utilized 
crDNA sequences combined with tracrRNA; all other reagent concentrations remained 
unaltered form the original protocol. Wells 10-13 show failed CRISPR-Cas9 reactions 
which utilized crDNA sequences only, but with pure, non-diluted template DNA and 3x 
the amount of Cas9 reagent; all other reagent concentrations remained unaltered form the 
original protocol. Wells 14 and 15 show failed CRISPR-Cas9 reactions which utilized 
crDNA sequences combined with tracrRNA, but with pure, non-diluted template DNA 
and 3x the amount of Cas9 reagent; all other reagent concentrations remained unaltered 
from the original protocol. 
 
 
Figure 3.3. Gel electrophoresis of an adapted version of the Origene-based CRISPR-
Cas9 protocol with increased template DNA concentrations and increased Cas9 reagent 
concentrations. Wells containing ladders are labeled with “L”. Wells containing uncut, 
stock PCR product are labeled “P”. Wells 3-6, 7, 8,10-13, 14 and 15 contain 






3.4 IDT Protocol Functionality Test 
 In the third experiment, the bands of uncut DNA still present in the reaction gel 
lanes were more apparent than they had been on the gel picture for experiment 1 (Figure 
3.4). The few lanes that contained reactions with 3X the amount of DNA (Lanes 11-14 
Figure 3.4) showed a faint 1,000bp band. Wells 3-6 show failed CRISPR-Cas9 reactions 
which utilized crDNA sequences combined with trcrRNA; the Cas9 reagent used in wells 
3-6 was from NEB (cat. # M0386T). Wells 7-10 show failed CRISPR-Cas9 reactions 
which utilized crDNA sequences combined with tracrRNA; the Alt-R Cas9 reagent used 
in wells 7-10 was from IDT (cat. # 1081058). Wells 11-14 show failed CRISPR-Cas9 
reactions which utilized crDNA sequences combined with tracrRNA, but with 3x the 




Figure 3.4. Gel electrophoresis of an adapted version of the IDT-based CRISPR-Cas9 
protocol. Wells containing ladders are labeled with “L”. Wells containing uncut, stock 
PCR product are labeled “P”. Well 2 does not contain any product. Wells 3-6, 7-10, and 
11-14 contain CRISPR/Cas9 reaction product. All reactions contained tracrRNA. Wells 





3.5 Adapted Origene and IDT Protocols 
 The fourth experiment reactions showed that reactions prepared with sgDNA 
resulted in no discernable difference from the other sets (Figure 3.5). This experiment 
also tested a wider variety of Cas9 amounts in each reaction; with no discernable 
difference in reaction results. Wells 3-10 show failed CRISPR-Cas9 reactions which 
utilized the IDT protocol; the Alt-R Cas9 reagent used in wells 3-10 was from IDT (cat. # 
1081058). Wells 13-20 show failed CRISPR-Cas9 reactions which utilized the IDT 
protocol; the Cas9 reagent used in wells 13-20 was from NEB (cat. # M0386T). Wells 
23-32 show failed CRISPR-Cas9 reactions which utilized the Origene protocol; the Cas9 
reagent used in wells 23-32 was from NEB (cat. # M0386T). 
 
 
Figure 3.5. Gel electrophoresis of CRISPR/Cas9 reaction products that were made using 
sgDNA sequences. Wells containing ladders are labeled with “L”. Wells containing 
uncut, stock PCR product are labeled “P”. Wells 3-10, 13-20, 23-32 contained 
CRISPR/Cas9 reaction product. The amount of cas9 (uL) added to each reaction is listed 
at the top. The first two sets of reactions utilized the IDT protocol; the last set of reactions 









4.1 Mendelian Genetics 
 CRISPR represents a unique opportunity in comparison to Mendelian methods of 
organism improvement. The initial goal of this research was to investigate whether 
CRISPR-Cas9 can knock-out dominant traits and remove the need for traditional genetic 
selection. Theoretically, CRISPR can knock-out any gene that has a PAM sequence in the 
correct location and a unique ~20bp sequence to match. Our objective was to combine 
the function of a restriction enzyme with the specificity of ZFN/TALEN procedures by 
using CRISPR/Cas9 to knock out a specific gene. Integrating these proved to be too 
optimistic for a single project.  The first step to this process would be to devise a 
targetable (and distinctive) restriction digest procedure. 
 
4.2 Restriction Enzymes 
 Restriction enzymes have proven to be a crucial tool in gene editing and have 
helped to improve the understanding of gene properties as a whole. CRISPR can take the 
basic application of restriction enzymes and improve upon that function by supplying a 
vast array of specific target sites that restriction enzymes do not have the flexibility to 





cost of RNA-based sgDNA and the lack of a simple method for in-vivo restriction. This 
project was unable to achieve either of these difficult tasks. 
 
4.3 Zinc Finger Nucleases and Transcription Activator-Like Endonucleases 
 ZFNs and TALENS have proven to be invaluable stepping stones to the 
development of new and improved gene altering technologies, namely CRISPR-Cas9. 
This research was to provide evidence to the fact that CRISPR-Cas9 has improved 
flexibility when compared to ZFNs or TALENS. Although all three types are usable for 
gene editing, the specificity of CRISPR is extremely attractive because it has the potential 
to be far more accessible to both experts and beginners alike. 
 
4.4 CRISPR Associated Protein/ CRISPR-Cas9 
 CRISPR-Cas9 is becoming the cutting edge of genetic research. Utilization of 
CRISPR-Cas9 can prove challenging due to its unique method of operation; however the 
overall process of using it lends itself well to easy reproducibility. These initial 
experiments sought to bring the functionality of the CRISPR system into widespread use 
as a restriction enzyme. It was at this point that we made the most fundamental mistake. 
We had attempted to utilize commercial protocols (IDT,Origene) for the application of 
CRISPR enzymes. Only to realize that these protocols were designed to introduce a gene 
into a sequence, that use selection protocols to identify successful integration. 
 The problem with our solution was dilution. These protocols required the dilution 
of our target DNA to undetectable (on agarose) levels. Even if our experiments had 






4.5 Project Outcomes 
 We sought to investigate three hypotheses. The first was that a user selectable 
restriction digest protocol could be created. The project resulted in failure to produce a 
simplified protocol, to successfully utilize CRISPR/Cas9 and to also make DNA 
sequences with Uracil replacing the Thymine bases to work with the Cas9 nuclease. For 
every experiment the choice was made to use crDNA sequences that were designed to 
produce fragments with disproportionately different sizes to enable easy visualization of 
a gel. If any of the digests had successfully been performed, the sizes would be roughly at 
2/8 ratio or a 6/4.  
 The majority of the reactions from the first and third experiments had heavily 
diluted reagents that resulted in the decreased possibility of visualizing a successful 
restriction. Not only was there a decreased possibility of seeing a successful restriction, 
but the resulting bands of un-successfully restricted DNA were also difficult (if not 
impossible) to visualize. This was most likely caused by the very small amounts of 
template DNA included in most of  the reactions. 
 Ideally a control would have been used to confirm the functionality of the 
reagents that were used. This step was initially skipped due to cost and time concerns. 
Ultimately, the testing of the reagents was not completed. The sheer cost associated with 
the traditional method of determining the functionality of reagents and then following 
through with subsequent troubleshooting would make this research impractical. If the 
expected approach was used then multiple variables would need to be tested. Comparing 
control Cas9 reaction with the experimental reactions would require standardization and 





 Although CRISPR/Cas9 is less specific in relation to ZFNs and TALENs, 
CRISPR/Cas9 has superior specificity to restriction enzymes. This research sought to 
compare the restriction potential of CRISPR/Cas9 to standard restriction enzymes. This 









 By testing the cleaving ability of CRISPR/Cas9 we hoped that a more user-
friendly and cost effective method of utilizing CRISPR/Cas9 could be devised to restrict 
specific DNA targets. We hoped that a more accessible and easy to understand protocol 
could be developed and that using DNA instead of RNA as a guide sequence would 
dramatacially reduce cost. If it is discovered that new combinations of genetic material 
and Cas9 can achieve a new function, this could potentially lead to specific, user 
selectable restriction digest capabilities. Although the experiments did not succeed, they 
have led to important insights that can be utilized in the next round of research. In future 
experiments, the concentration of end product will be increased or the capacity to detect 
this product will be improved. In addition, the manipulation of provided controls will be 
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